353 related articles for article (PubMed ID: 23241899)
1. What lessons can be learned from γδ T cell-based cancer immunotherapy trials?
Fournié JJ; Sicard H; Poupot M; Bezombes C; Blanc A; Romagné F; Ysebaert L; Laurent G
Cell Mol Immunol; 2013 Jan; 10(1):35-41. PubMed ID: 23241899
[TBL] [Abstract][Full Text] [Related]
2. Role of gamma-delta T-cells in cancer: another opening door to immunotherapy.
Marquez-Medina D; Salla-Fortuny J; Salud-Salvia A
Clin Transl Oncol; 2012 Dec; 14(12):891-5. PubMed ID: 23054752
[TBL] [Abstract][Full Text] [Related]
3. Harnessing γδ T cells in anticancer immunotherapy.
Hannani D; Ma Y; Yamazaki T; Déchanet-Merville J; Kroemer G; Zitvogel L
Trends Immunol; 2012 May; 33(5):199-206. PubMed ID: 22364810
[TBL] [Abstract][Full Text] [Related]
4. Strategies to Improve the Antitumor Effect of γδ T Cell Immunotherapy for Clinical Application.
Miyashita M; Shimizu T; Ashihara E; Ukimura O
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445615
[TBL] [Abstract][Full Text] [Related]
5. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors.
Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S
Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354
[TBL] [Abstract][Full Text] [Related]
6. γδ T-cell immunotherapy for lung cancer.
Yoshida Y; Nakajima J; Wada H; Kakimi K
Surg Today; 2011 May; 41(5):606-11. PubMed ID: 21533930
[TBL] [Abstract][Full Text] [Related]
7. The promise of γδ T cells and the γδ T cell receptor for cancer immunotherapy.
Legut M; Cole DK; Sewell AK
Cell Mol Immunol; 2015 Nov; 12(6):656-68. PubMed ID: 25864915
[TBL] [Abstract][Full Text] [Related]
8. How tumors might withstand γδ T-cell attack.
Capietto AH; Martinet L; Fournié JJ
Cell Mol Life Sci; 2011 Jul; 68(14):2433-42. PubMed ID: 21547501
[TBL] [Abstract][Full Text] [Related]
9. The Role of Human γδ T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy.
Liu Y; Zhang C
Cells; 2020 May; 9(5):. PubMed ID: 32413966
[TBL] [Abstract][Full Text] [Related]
10. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies.
Sebestyen Z; Prinz I; Déchanet-Merville J; Silva-Santos B; Kuball J
Nat Rev Drug Discov; 2020 Mar; 19(3):169-184. PubMed ID: 31492944
[TBL] [Abstract][Full Text] [Related]
11. γδ T cells in cancer immunotherapy.
Zou C; Zhao P; Xiao Z; Han X; Fu F; Fu L
Oncotarget; 2017 Jan; 8(5):8900-8909. PubMed ID: 27823972
[TBL] [Abstract][Full Text] [Related]
12. [γδ T cell-based cancer immunotherapy].
Matsushita H; Kakimi K
Nihon Rinsho; 2017 Feb; 75(2):301-305. PubMed ID: 30562868
[TBL] [Abstract][Full Text] [Related]
13. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.
Rei M; Pennington DJ; Silva-Santos B
Cancer Res; 2015 Mar; 75(5):798-802. PubMed ID: 25660949
[TBL] [Abstract][Full Text] [Related]
14. Aminobisphosphonates as new weapons for gammadelta T Cell-based immunotherapy of cancer.
Caccamo N; Meraviglia S; Cicero G; Gulotta G; Moschella F; Cordova A; Gulotta E; Salerno A; Dieli F
Curr Med Chem; 2008; 15(12):1147-53. PubMed ID: 18473809
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and some immunological properties of gammadelta T-cells from patients with gastrointestinal carcinomas.
Murayama M; Tanaka Y; Yagi J; Uchiyama T; Ogawa K
Anticancer Res; 2008; 28(5B):2921-31. PubMed ID: 19031935
[TBL] [Abstract][Full Text] [Related]
16. Expression of intercellular adhesion molecule (ICAM)-1 or ICAM-2 is critical in determining sensitivity of pancreatic cancer cells to cytolysis by human gammadelta-T cells: implications in the design of gammadelta-T-cell-based immunotherapies for pancreatic cancer.
Liu Z; Guo B; Lopez RD
J Gastroenterol Hepatol; 2009 May; 24(5):900-11. PubMed ID: 19175829
[TBL] [Abstract][Full Text] [Related]
17. γδ T-cell conference 2012: close encounters for the fifth time.
Silva-Santos B; Schamel WW; Fisch P; Eberl M
Eur J Immunol; 2012 Dec; 42(12):3101-5. PubMed ID: 23255005
[TBL] [Abstract][Full Text] [Related]
18. γδ T Cells: The Ideal Tool for Cancer Immunotherapy.
Yazdanifar M; Barbarito G; Bertaina A; Airoldi I
Cells; 2020 May; 9(5):. PubMed ID: 32456316
[TBL] [Abstract][Full Text] [Related]
19. The Ambiguous Role of γδ T Lymphocytes in Antitumor Immunity.
Chitadze G; Oberg HH; Wesch D; Kabelitz D
Trends Immunol; 2017 Sep; 38(9):668-678. PubMed ID: 28709825
[TBL] [Abstract][Full Text] [Related]
20. Harnessing the power of Vδ2 cells in cancer immunotherapy.
Fowler DW; Bodman-Smith MD
Clin Exp Immunol; 2015 Apr; 180(1):1-10. PubMed ID: 25469879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
